Hair loss management is increasingly moving towards personalised and multimodal approaches, with non-invasive technologies gaining attention alongside established pharmacological and procedural treatments. Low-Level Light Therapy (LLLT), also known as photobiomodulation, has emerged as an option for supporting hair growth, particularly in androgenetic alopecia.
L3Tx, a home-use LLLT device from Kshipra Health Solutions, uses 120 medical-grade LEDs delivering light at approximately 640 nm and is designed for a 10-minute daily treatment protocol. The device has received US FDA 510(k) clearance and is being positioned as a technology-enabled, non-pharmacological approach that can complement existing hair-loss treatment strategies.
In this interview with MedTech Spectrum, Kirtesh Jain, CEO, Kshipra Health Solutions, discusses the clinical evidence supporting LLLT, the technology and dosing considerations behind L3Tx, its potential role alongside treatments such as Minoxidil, Finasteride, PRP and GFC, and the importance of clinical supervision and patient adherence in home-based therapy. He also outlines Kshipra Health Solutions' vision for technology-enabled hair restoration and the company's approach to bringing globally developed medical technologies to patients in India.
What clinical evidence and validation underpin L3Tx’s use of Low-Level Light Therapy (LLLT) for hair regrowth?
Low-Level Light Therapy, or LLLT, has been studied for several years as a non-invasive approach to managing hair loss, particularly androgenetic alopecia. Clinical studies and systematic reviews have reported improvements in parameters such as hair density, hair thickness and overall hair coverage compared with sham or placebo treatment.The evidence suggests that appropriately dosed red light can influence cellular activity within the hair follicle and support the anagen, or growth, phase of the hair cycle. Importantly, the response is progressive rather than immediate. Patients generally need consistent treatment over several months to assess meaningful changes.
L3Tx is built around this established photobiomodulation principle and is designed to provide a standardized, repeatable treatment experience at home. As with any hair-loss therapy, outcomes can vary depending on the underlying cause of hair loss, stage of disease, individual biology and treatment adherence.
L3Tx uses 120 medical-grade LEDs at approximately 640 nm. What was the rationale behind this wavelength and LED configuration?
The wavelength is an important part of photobiomodulation because biological responses depend on the wavelength and dose of light delivered to the tissue.
Red-light wavelengths in the approximate 600–700 nm range have been extensively investigated in hair-growth research, with wavelengths around the 630–680 nm range commonly represented in clinical studies. L3Tx uses approximately 640 nm as part of this evidence-based approach.
The 120-LED configuration is designed to provide broad and consistent illumination across the scalp. Rather than concentrating light in a small area, the objective is to achieve more uniform coverage of the treatment zone.
Ultimately, it is not simply the number of LEDs that matters. Wavelength, irradiance, treatment duration, energy delivered and scalp coverage all contribute to the overall photobiomodulation dose. L3Tx has been designed with these parameters in mind to make light delivery consistent and practical for home use.
How does L3Tx complement conventional hair-loss treatments such as Minoxidil, Finasteride, PRP and GFC?
Hair loss is a multifactorial condition, and there is no single approach that is appropriate for every patient. LLLT offers a different, non-pharmacological mechanism and can therefore be considered as part of a broader, multimodal treatment strategy.
Conventional treatments such as Minoxidil and Finasteride work through pharmacological mechanisms, while PRP and GFC are injectable approaches. Photobiomodulation uses controlled light energy to stimulate biological processes associated with follicular function.
For suitable patients, particularly those with early-to-moderate androgenetic alopecia or those looking for a non-invasive adjunct to their existing treatment, LLLT can be incorporated into a dermatologist-supervised treatment plan.
The key is personalization. The underlying diagnosis, stage of hair loss, previous treatment response, lifestyle and patient preferences should all determine where LLLT fits into the overall treatment protocol.
The device is designed for 10 minutes of daily use at home. What measures have been incorporated to ensure consistent dosing, safety and adherence?
One of the biggest challenges with any long-term hair-loss treatment is adherence. We wanted to make the treatment simple enough to become part of a patient's routine without adding significant time or complexity.
The 10-minute protocol provides a defined treatment duration and helps standardize exposure. The device's LED configuration is designed to provide consistent scalp coverage, while the overall device architecture is intended to make positioning and treatment straightforward for the user.
However, technology should not replace clinical judgment. Dermatologists have an important role in diagnosing the type and stage of hair loss, determining whether LLLT is appropriate, establishing the treatment protocol and monitoring progress.
For us, the goal is to combine clinical supervision with the convenience of technology-enabled home care.
L3Tx is described as a US FDA-cleared medical device. Could you elaborate on its regulatory status and the pathway for adoption in India?
L3Tx has undergone the US FDA 510(k) regulatory pathway, which is the established premarket pathway for demonstrating that a medical device is substantially equivalent to a legally marketed predicate device. The device has met the applicable requirements for this pathway and received FDA clearance. For us, this represents an important validation of the device's safety, performance and intended use within the applicable regulatory framework. In India, we are following the relevant CDSCO and Medical Device Rules requirements for its adoption and use, with the focus remaining on bringing clinically supported technology to patients in a safe and responsible manner. Our approach is to ensure that L3Tx's introduction and use in India follow the relevant regulatory requirements and are supported by appropriate technical and clinical documentation. Our objective is to bring global technology to Indian patients while maintaining the same emphasis on safety, evidence and responsible clinical use.
What is Kshipra Health Solutions' broader vision for technology-enabled hair restoration in India?
At Kshipra Health Solutions, our vision is to improve lives by redefining treatment experiences through unique and innovative solutions.
Our mission is to drive innovation, excellence and knowledge leadership, while keeping patients and customer service at the heart of everything we do. L3Tx is a step towards this vision bringing innovative, non-invasive technology into the hair-restoration journey and creating better treatment experiences for patients.
